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Available online 15 January 2017Mucopolysaccharidosis I and II are lysosomal storage disorders that, despite treatment with hematopoietic cell
transplantation (HCT) and/or enzyme replacement therapy (ERT), continue to cause significant skeletal abnor-
malities leading to pain, stiffness, physical dysfunction, and short stature. Tumor necrosis factor – alpha (TNF-
α) is elevated in individuals with MPS I and II and associated with pain and physical dysfunction. Therefore,
we evaluated the safety and effects of the TNF-α inhibitor adalimumab in patients with MPS I and II in a 32-
week, randomized, double blind, placebo-controlled, crossover study of adalimumab at a dose of 20 mg (weight
15–b30 kg) or 40 mg (weight ≥30 kg) administered subcutaneously every other week or saline placebo for
16 weeks. Participants were evaluated at baseline, week 16, and week 32 with the Children's Health Question-
naire – Parent Form 50 (CHQ-PF50), the Pediatric Pain Questionnaire (PPQ), range-of-motion (ROM) measure-
ments, anthropometry, six-minute walk test (6MWT), hand dynamometer, and laboratory evaluations for
safety. The primary outcome was safety and primary efficacy outcome was bodily pain (BP) measured by the
CHQ-PF50. Two subjects, one with MPS I and one with MPS II, completed the study. Adalimumabwaswell toler-
ated and there were no serious adverse events. Standardized BP scores for age and gender were higher (i.e. less
pain) at the end of the treatment versus placebo phase for both subjects. Subject #1 became unblinded during
treatment due to skin erythema. Behavior measured by both CHQ-PF50 and parental report improved during
treatment compared to placebo in both subjects. ROM improved by N5° in seven of eight joints in Subject #1
and five of eight joints in Subject #2 (range 7.0° to 52.8°). There was no change in the PPQ, 6MWT, or hand dy-
namometer. Data from this small pilot study suggest that treatment with adalimumab is safe, tolerable, andmay
improve ROM, physical function, and possibly pain, in childrenwithMPS I or II. However, additional clinical trials
are needed before this therapy should be recommended as part of clinical care.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Mucopolysaccharidosis
Inflammation
Joint
Bone1. Introduction
The mucopolysaccharidoses (MPS) are a group of lysosomal storage
diseases resulting from specific lysosomal enzyme deficiencies that re-
sult in lysosomal accumulation of glycosaminoglycans (GAG) in most
body tissues. Despite treatmentwith hematopoietic cell transplantation
(HCT) and/or enzyme replacement therapy (ERT), individuals withMPS
I or II continue to have significant skeletal abnormalities (i.e., kyphosis,s Angeles Biomedical Research
rson Street, Liu Research Bldg,
en), kunin003@umn.edu
1@umn.edu (R.K. Vehe),
itley), pdickson@labiomed.org
. This is an open access article underscoliosis, genu valgum), joint contractures, stiffness, pain, and severe
short stature [1–6].
GAG deposition has been identified in bone and cartilage in humans
and animal models of MPS [7–15]. This deposition in cartilage induces
inflammation, chondrocyte apoptosis, and hyperplasia of the synovial
membranes ofMPS animals [12,14], and is similar to joint changes in ju-
venile idiopathic arthritis (JIA), rheumatoid arthritis (RA), and ankylos-
ing spondylitis (AS) [12–16]. In animalmodels ofMPS, GAG continues to
accumulate despite treatmentwith ERT, and accumulatedGAG activates
toll-like receptor-4 (TLR-4), similar to lipopolysaccharide (LPS), in
synovial chondrocytes and monocyte/macrophages [13,14,17]. TLR-4
activation increases expression and secretion of TNF- α, interleukin -
1β (IL-1β), and receptor activator of nuclear factor kappa-B ligand
(RANKL) resulting in local inflammatory joint disease and systemic in-
flammation [12,13,17,18]. Matrix-degrading metalloproteinases
(MMP-1, -2, -9, and -13) are also elevated in the MPS I and VI animals,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nally, localized increased bone resorption in bone surrounding knee
joints of MPS I mice [16], and proteoglycan loss in joints of MPS IX ani-
mals [19] has been reported.
MPS animalmodels show improvement in joint disease andmobility
after treatment with TNF-α inhibition [13,15]. Presymptomatic MPS VI
rats treated with a rat specific TNF- α inhibitor in addition to ERT (re-
combinant human N-acetylgalactosamine-4-sulfatase) developed sig-
nificantly less synovial villi (marker of joint inflammation that is seen
in rheumatoid arthritis), a greater improvement in performance on
rotarod testing at higher speeds (20 and 30 RPM), and a trend toward
increased femora (6% longer) and tibia (14% longer) lengths, compared
to animals treatedwith ERT alone [15]. In another study of 6-month-old
MPSVI ratswith advanced bonedisease and 1-month-old presymptom-
aticMPS VI rats treatedwith the TNF-α inhibitor infliximab, TNF-α and
RANKL levels decreased to levels similar to normal rats within 4–
8 weeks post-injection, and in the 6-month-old MPS VI rats with ad-
vanced bone disease, the percent of apoptotic cells in articular cartilage
measured by TUNEL staining decreased significantly from that seen in
untreated animals and was no different than in normal animals [16].
Furthermore, children and adolescentswithMPS have elevated plas-
ma levels of TNF-α and high levels of TNF-α directly correlatewith their
severity of pain and decreased physical function [20]. This is not surpris-
ing as TNF-α has a myriad of well-described local and systemic effects.
For example, TNF-α 1) incites further inflammation through activation
of monocytes to inflammatory macrophages that produce other cyto-
kines such as IL-1β and RANKL, 2) recruits neutrophils and other phago-
cytes, 3) causes cellular apoptosis, and 4) increases endothelial
permeability, all of which drive further inflammation. In addition,
TNF-α is involved in the release of prostanoids such as prostaglandin
E2 that cause systemic pain (i.e. myalgia). This cascade of events causes
collateral tissue damage and joint abnormalities, systemic inflamma-
tion, and pain as is characteristic of rheumatologic joint diseases [21,
22] and MPS.
In summary, 1) animalmodels ofMPS have revealed joint abnormal-
ities similar to those seen in inflammatory joint disease and improve-
ment in inflammation, joint pathology, and physical function when
treated with TNF- α inhibition, and 2) individuals with MPS have high
levels of plasma TNF-α that are associated with pain and physical dis-
ability despite current therapies. Therefore, we conducted a pilot
study to collect data on the safety, tolerability and effect of adalimumab
(AbbVie) on pain and physical function in individuals with MPS I or II.
Secondary objectives included evaluating the effects of adalimumab
on ROM, growth, endurance (6MWT), and muscle strength (handgrip
dynamometer).
2. Methods
2.1. Patients and screening
Inclusion criteria were age ≥5 years of age, diagnosis of MPS I or II
(genetic testing or enzyme activity plus elevated urine GAG), treatment
with ERT for ≥1 year or no ERT for ≥1 year, weight ≥15 kg, bodily pain
reported by the CHQ-PF50 or SF-36 N 1 SD below the general population
mean (i.e. more pain), and ≥3 joints with limitations in ROM. Exclusion
criteria were history of HCT b2 years prior to enrollment, immune sup-
pression therapy b1 year prior to enrollment, active graft versus hostTable 1
Subject baseline characteristics.
Patient no. Sex/age (yr) Diagnosis ERT (y/n)
1 M/15 Hurler syndrome No
2 M/6 Hunter syndrome – attenuated Yes
M-male; ERT = enzyme replacement therapy; HCT = hematopoietic cell transplantation; GAGdisease, current diagnosis or history of lymphoma or other malignancy,
current active infection, history of serious opportunistic infection, posi-
tiveM. tuberculosis (TB) skin test, positive chest X-ray, or a recent expo-
sure to TB, congestive heart failure defined by an ejection fraction b50%
measured by ECHO, demyelinating disorders (e.g., central nervous sys-
tem [CNS] disorders including multiple sclerosis and optic neuritis and
peripheral nervous system disorders including Guillain-Barre syn-
drome), hematologic abnormalities (e.g., pancytopenia, aplastic ane-
mia), hepatitis B infection (active or chronic carrier), latex sensitivity,
pregnancy or breastfeeding, known or suspected allergy to adalimumab
or related products, participation in simultaneous therapeutic study
that involved an investigational study drug or agent within 4 weeks of
study enrollment, and requirement for live vaccine exposure that
would be expected to occur during the time frame of the study.
Informed consent was obtained from all parents/guardians of the
subjects and assent from subjects cognitively able to provide assent.
The Los Angeles Biomedical Research Institute John F. Wolf, M.D.
Human Subjects Committee approved the protocol.
2.2. Design
This was a randomized, double blind, placebo-controlled, 32-week,
crossover pilot study of adalimumab in subjects withMPS I or II treated
with ERT and/or HCT. Subjects were randomized 1:1 in a permuted
block fashion with potential block sizes of 2. Subjects were treated
with adalimumab or placebo for 16 weeks (i.e., 8 doses) then crossed
over to the other group for 16 weeks. Subjects were treated with
adalimumab (20 mg [weight 15–b30 kg] or 40 mg [weight ≥30 kg]) or
saline placebo administered subcutaneously every other week for
16weeks, then crossed-over to the other group for 16weeks. The place-
bo was similar to the active treatment in appearance.
At the screening visit the patient's symptoms, medical history, de-
mographic and clinical characteristics were recorded, eligibility was
confirmed, and eligible patients randomized as described above. Parents
were given a diary and were asked to record date of injections, symp-
toms, any other pain or anti-inflammatory medications, and adverse
events.
Measurements of pain, physical function, and anthropometry were
measured at baseline (day 0), weeks 16 and 32. The baseline visit oc-
curred on the same day as the screening visit. Pain was measured by
the Children's Health Questionnaire – Parent Form 50 (CHQ-PF50) and
the Pediatric Pain Questionnaire (PPQ). The CHQ-PF50 Bodily Pain
(BP) Score evaluates parent-report of both severity and frequency of
their child's bodily pain over the past 4 weeks, and the PPQ includes a
parent- and a patient-reported visual analogue scale consisting of two
100 mm horizontal lines that measure both present pain and pain in
the past week. Physical function was measured by the CHQ-PF50 Phys-
ical Function (PF) Score and Physical Summary (PhS) Score, ROM, 6-
minute walk test (6MWT), and hand-grip dynamometer. The CHQ-
PF50 evaluates parent-report of limitations in their child's physical
function in activities such as play, getting around school, climbing stairs,
and taking care of activities of daily living (e.g. eating, dressing, bathing,
going to the toilet). Additional quality of life and behavioral outcomes
were measured by CHQ-PF50. ROMwas measured by the same two in-
dividuals at each visit. ROM sites (shoulder flexion, elbow extension,
knee extension, and hip extension) were chosen based on common
areas of MPS related disease. Anthropometric measurements (standingh/o HCT (y/n) Diagnosis
Yes Urine GAG 139.9 mg/L
Leukocyte α-L-iduronidase activity 0 nmol/h/mg protein
No 260GNA IDS gene mutation
= glycosaminoglycans; IDS = iduronate-2-sulfatase.
Table 3
Changes inCHQ-PF50 Z-scores (adjusted for age and gender) during treatment (Tx) versus
placebo (PBO). N0.5 SDS improvements are bolded.
Outcomes Treatment change Placebo change Difference Tx-PBO
Patient no. Patient no. Patient no.
1 2 1 2 1 2
PhS 1.0 0.7 0.0 0.6 1.0 0.1
PsS 0.4 0.4 −0.8 0.3 1.2 0.1
GH 0.2 0.2 0.4 1.1 −0.2 −0.9
BP 0.0 0.5 −1.4 −0.5 1.4 1.0
PF 0.7 1.4 0.7 1.0 0.0 0.4
RP 1.8 0.0 0.0 0.0 1.8 0.0
PT 1.1 0.0 −1.1 0.5 2.2 −0.5
PE 0.0 1.2 −0.4 0.8 0.4 0.4
REB 1.7 0.0 −1.7 0.0 3.4 0.0
SE -0.5 0.2 0.0 0.9 −0.5 −0.7
MH 0.7 0.4 0.0 0.7 0.7 −0.3
BE 0.0 0.5 −0.7 −1.0 0.7 1.5
PF = physical functioning; RP = role/social-physical; GH= general health; BP = bodily
pain (lower=worse pain); PT=parental impact-time; PE=parental impact-emotional;
REB = role/social-emotional/behavioral; SE = self-esteem; MH= mental health; BE =
behavior; PhS= Physical Health Summary Score (PF, RP,GH, BP, PT, PE); PsS= Psychoso-
cial Health Summary Score (PT, PE, REB, SE, MH, BE); increase means an improvement for
all scales except BP (bodily pain) where increase in score = decrease in pain.
Table 2
Adverse events.
Patient no. Event Severity During treatment or placebo? Comments
1 Diarrhea Mild Treatment Resolved after 2 days without intervention.
1 Thrombocytopenia Mild Treatment Resolved by 2 week recheck without intervention
1 Mood lability Mild Placebo Persisted until the end of the study
1 URI Mild Placebo Resolved with 10 days antibiotic therapy.
1 Headache Mild Placebo Resolved with ibuprofen
2 Sinusitis Mild Placebo Resolved on day 3 of 10 day antibiotic therapy.
2 URI Mild Placebo Resolved on day 7 of 10 day antibiotic therapy.
2 Injection site erythema Mild Treatment Lasted up to 24 h with each injection
URI = upper respiratory infection.
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the average taken. Urine GAG was measured by Spectrophotometry
(Mayo Medical Laboratories; Rochester, MN) a baseline, weeks 16 and
32. Safety was assessed with physician obtained history and physical
examination and laboratory evaluations (complete blood count [CBC],
liver function tests [LFTs], and anti-double stranded DNA [anti-dsDNA]
antibodies) at baseline, weeks 16 and 32; safety laboratory evaluations
were also obtained at weeks 4, 8, 20, and 24.
2.3. Statistical analysis
Data are presented in descriptive fashion due to the small sample
size of this pilot study. All analyses and graphing were performed with
the use of STATA software, version 14.0.
3. Results
3.1. Study participants
Three participants enrolled in the study and two participants com-
pleted the study (see Table 1). One withdrew before randomization
for reasons unrelated to the study. Two subjects underwent randomiza-
tion, completed all study visits, and are included in this report. The rate
of adherence to study drug was 100% as assessed according to diary en-
tries and 100% as assessed according to the amount of returned study
drug syringes.
3.2. Safety outcomes
Adverse events occurred in both subjects during treatment with
adalimumab (100%) and during placebo (100%) (Table 2). All adverse
events were classified as mild in severity and resolved spontaneously
except for sinusitis and two upper respiratory infections (URIs) that re-
quired oral antibiotic therapy (all occurring during placebo). Subject #1
experienced mood lability beginning approximately 4 weeks after the
last adalimumab dose that was reported by both the patient's teachers
and parents. All safety laboratory evaluations were normal throughout
the study except transient mild thrombocytopenia occurring in Subject
#1 described in Table 5.
3.3. Primary efficacy outcome - pain (CHQ-PF50, PPQ)
Changes of 5.0 to 10.0 points on the CHQ-PF50 are considered to be
clinically meaningful [23–25]. Using this metric, both subjects had a
positive response to treatment (Table 3 and Fig. 1). Although Subject
#1 had no change in pain during treatment with active drug, he had a
significant increase in pain (decrease in the Bodily Pain Score) when
he switched to placebo (Fig. 1). Subject #2 had an increase in pain of
10 points during placebo and a decrease of 10 points during treatment
(Fig. 1). Standardization of these scores for age and gender showed an
improvement of +1.4 standard deviations (SD) in Subject #1 and
+1.0 SD in Subject #2 in change of CHQ-PF50 BP scores duringtreatment versus placebo (Table 3). There was no significant benefit in
reported pain when measured by the PPQ (data not shown).
3.4. Secondary efficacy outcomes - CHQ-PF50, physical function (ROM,
6MWT, handgrip), anthropometry, and urine GAG
Physical function, behavioral and quality-of-life outcomesmeasured
by the CHQ-PF50 are shown in Table 4 and Fig. 1.When using a cutoff of
a difference in change of N0.5 SD, Subject #1 had a positive response
during treatment compared to placebo for 8 of the 12 CHQ-PF50 out-
come measures and patient #2 had a positive response in 2 of the 12
outcome measures. Improvements in bodily pain and behavior were
the only two measures with improvements during treatment in both
subjects. Both subjects had a worsening of standardized scores on the
CHQ-PF50 for General Health (GH) and Self Esteem (SE); Subject #2
also had a worsening in Parental Impact-Time (PT) and Mental Health
(MH).
For ROM(Table 4), Subject #1 had a positive response (defined as an
improvement in ROM of N5° during treatment compared to placebo) to
adalimumab versus placebo in bilateral shoulder flexion, bilateral elbow
extension, left knee extension, and bilateral hipflexion. Subject #2 had a
positive response to adalimumab versus placebo in the right shoulder
flexion, bilateral elbow extension, bilateral knee extension, and right
hip flexion. There was no effect on 6MWT or handgrip (data not
shown).
Anthropometric data are shown in Table 5. Growth velocity (annual-
ized cm/yr change in standing height) was N2 cm/yr higher during
treatmentwith adalimumab versus placebo in both subjects. For Subject
Fig. 1. Changes in pain (BP), physical function (PF), Physical Health Summary Score (PhS), and Psychosocial Health Summary Score (PsS) measured by the CHQ-PF50, during treatment
versus placebo. Increase in score means an improvement for all scales except BP where increase in score = decrease in pain.
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during placebo and unchanged or positive during treatment, possibly
suggesting an increase in contracture during placebo versus treatment.
For Subject #2 the arm span and sitting height annualized change was
greater during placebo versus treatment. Possible reasons for these
findings are improved arm growth and spine growth during placebo,
and/or measurement error/variability.Table 4
Changes in range-of-motion (ROM) during treatment (Tx) versus placebo (PBO). N5° im-
provements are bolded.
Outcomes Treatment change Placebo change Difference
Tx-PBO
Patient no. Patient no. Patient no.
1 2 1 2 1 2
Shoulder flexion – left, ° −0.5 20.2 −13.5 43.8 13.0 −23.6
Shoulder flexion – right, ° 10.5 49.2 −17.5 23.2 28.0 26.0
Elbow extension – left, ° 5.8 17.3 −2.5 −13.7 8.3 31.0
Elbow extension – right, ° 21.3 19.0 −10.0 −16.0 31.3 35.0
Hip extension – left, ° 41.3 −13.8 −11.5 −11.1 52.8 −2.7
Hip extension – right, ° 31.5 4.8 0.0 −2.2 31.5 7.0
Knee extension – left, ° 0.3 14.3 −11.5 −10.4 11.8 24.7
Knee extension – right, ° −7.3 6.7 1.0 4.4 −8.3 2.3There was no change in urine GAG during the study. Subject #1
urine GAG at baselinewas 6.3mg/mmol creatinine, 5.7mg/mmol creat-
inine after 16 weeks treatment, and then 6.2 mg/mmol creatinine after
16 weeks placebo (normal for age b 6.5 mg/mmol creatinine). Subject
#2 urine GAG at baseline was 17.4 mg/mmol creatinine, 16 mg/mmol
creatinine after 16 weeks placebo, and then 18 mg/mmol creatinine
after 16 weeks treatment (normal for age b 12 mg/mmol creatinine).
3.5. Anecdotal responses
Parents provided feedback throughout the study in a journal and by
unsolicited emails; in addition, parents were queried at the completionTable 5
Anthropometric measures during treatment (Tx) versus placebo (PBO). N2 cm/yr im-
provements are bolded.
Outcomes Treatment Placebo Difference Tx-PBO
Patient no. Patient no. Patient no.
1 2 1 2 1 2
Standing height, cm/yr 0.1 9.4 −2.7 4.2 2.8 5.2
Arm span, cm/yr 3.3 4.8 −7.6 10.4 10.9 −5.6
Sitting height, cm/yr −0.1 1.0 0.9 4.5 −1.0 −3.5
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to therapy. Quotes fromparents' observations after stopping adalimumab
(first quote before unblinding; second quote after unblinding):
“… behaviors have been increased the past two days. May be in pain...
Behaviors are still increased. Seems to be one extreme to another… I
had calls from his teacher twice last week and extreme behavior at
home once this week.”
“… has stopped drawing completely because of the joint pain. He is also
back to being more emotional towards the end of the day... His physical
therapist also noticed that his range of motion has gotten worse… The
only thing this has changed is him being off the Humira.”
4. Discussion
This studydescribes the use of a TNF-α inhibitor in twopatientswith
MPS.We found that adalimumabwaswell tolerated and that it had ben-
eficial clinical effects on pain, range-of-motion, behavior and growth in
both participants, one with MPS type I and one with MPS type II.
TNF-α is elevated in individuals withMPS I or II [20] and contributes
to pain through both driving a local inflammatory response and releas-
ing prostanoids such as prostaglandin E2 that cause systemic pain (i.e.
myalgia) [21]. We hypothesize that the benefit in pain management
seen in both of our subjects was directly related to inhibition of this
pathway. Of note, Subject #1 had no significant improvement in CHQ-
PF50 BP score during treatment with adalimumab, which could be
interpreted as no benefit from treatment, or as a benefit from treatment
when comparing the BP score at the end of placebo which was lower
(i.e. more pain) versus the end of treatment. Using this approach, in
Subject #1 there is a treatment effect of 43% (BP standardized score at
Baseline 70, Week 16 70, Week 32 40) and CHQ-BP50 BP score treat-
ment effect in Subject #2 was 33% (BP standardized score at Baseline
40, Week 16 30, Week 32 40).
Joint stiffness persists as a significant problem for patients with MPS
I and II despite treatmentwith ERTor HCT [26–29]. One 12-month study
of ERT in patientswithMPS II reported changes in ROMof up to 19° [28].
In comparison, we found changes of up to 35° following treatment with
adalimumab in the participant with MPS II (Subject #2), who was on
ERT at study entry. For MPS I, one retrospective chart review found se-
vere ROM deficits (defined as restriction of ≥90° for shoulder abduc-
tion) in five out of sixteen patients [29]. The effects of ERT on joint
ROM in patients with MPS IA (attenuated MPS I; Hurler-Scheie and
Scheie syndromes) have been well described [30–32]. One study
found that after 2 years of treatment with laronidase, patients with
MPS IA had on average improvements in shoulder flexion of 29°
(range 5°–50°) [31]. We found comparable changes of 13° and 28° in
the participantwithMPS type IH (Subject #1),whohad been previously
treated with hematopoietic stem cell transplantation, over just
16 weeks of treatment with adalimumab.
Both subjects had significant worsening of behavior measured by
the CHQ-PF50 Behavior Score and by parental report after discontinua-
tion of adalimumab. It is possible that some of the difficult behaviors in
children with MPS who are cognitively delayed may be related to pain.
For example, for Subject #1, both his teachers and parents noticedwors-
ening in his behavior and mood beginning approximately 4 weeks after
his last dose of adalimumab and his parent reported increased pain dur-
ing treatment with placebo compared to adalimumab. Worsening in
pain, mood, and behavior also occurred for Subject #2 approximately
4 weeks after discontinuing adalimumab per parental report (after the
conclusion of the study). Studies in patients with rheumatoid arthritis
suggest that the effects of adalimumab can last for 4 weeks to 3 months
after cessation of therapy, consistent with our observations [33].
The primary safety concern when treating with TNF-α inhibitors,
like adalimumab, is infection particularly disseminatedM. tuberculosis.We screened both subjects forM. tuberculosis exposure at baseline and
both were negative. Neither developed a chronic cough during the
treatment period and so no further testing for tuberculosis was
performed. Other more common infections reported to increase during
treatment with adalimumab include sinusitis (11%) and upper respira-
tory infections (17%); headache is also common (12%). These AEs
occurred in both subjects during treatment with placebo, and are com-
mon ailments in patients with MPS.
This study is limited by the small sample size. The duration of the
study is short, particularly for the safety outcomes. Finally, the presence
of erythema at the injection sites for Subject #2 in effect unblinded the
parents, subject, coordinators, and PI; however, the individuals who
measured ROM and anthropometry were not privy to this information
and so remained blinded throughout the study. This unblinding of the
subject and parents may have influenced their responses to the CHQ-
PF50 and the PPQ where the parents' response on the CHQ-PF50 indi-
cated improvement at the end of the treatment phase versus the
subject's response on the PPQ indicated no significant improvement.
However, this discrepancy was present for Subject #1 as well where
the blinding was maintained and the parent answered both pain ques-
tions due to cognitive limitations of Subject #1. Despite these limita-
tions, we found improvements in ROM, behavior, and growth in both
subjects during treatment with adalimumab.5. Conclusions
In conclusion, although joint and other skeletal disease in MPS are
complex and likely due to a multifaceted interplay of inflammatory
and mechanical factors, data from this small pilot study suggests that
treatment with adalimumabmay improve physical function, and possi-
bly pain, in childrenwithMPS I or II. A larger study of adalimumab in in-
dividuals with MPS I and II is indicated.Acknowledgements
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